-
1.发明申请LENTIVIRAL VECTORS PSEUDOTYPED WITH A SINDBIS VIRUS ENVELOPE GLYCOPROTEIN 审中-公开使用SINDBIS VIRUS ENVELOPE GLYCOPROTEIN的LENIVEIRAL VECTORS PSEUDOTYPED公开(公告)号：US20110064763A1
公开(公告)日：2011-03-17
申请号：US12842609
申请日：2010-07-23
摘要： Lentiviral vector particles comprising a Sindbis virus E2 glycoprotein variant and a lentiviral vector genome comprising a sequence of interest are provided. A lentiviral vector particle comprising: (a) an envelope comprising a Sindbis virus E2 glycoprotein variant; and (b) a lentiviral vector genome comprising a sequence of interest; wherein the E2 glycoprotein variant facilitates infection of dendritic cells by the lentiviral vector particle, and wherein the E2 glycoprotein variant has reduced binding to heparan sulfate compared to a reference sequence (HR strain).
摘要翻译： 提供包含辛德毕斯病毒E2糖蛋白变体和包含感兴趣序列的慢病毒载体基因组的慢病毒载体颗粒。 一种慢病毒载体颗粒，包括：（a）包含辛德毕斯病毒E2糖蛋白变体的包膜; 和（b）包含感兴趣序列的慢病毒载体基因组; 其中E2糖蛋白变体便于慢病毒载体颗粒感染树突状细胞，并且其中E2糖蛋白变体与参考序列（HR应变）相比具有减少的与硫酸乙酰肝素的结合。
-
2.发明授权公开(公告)号：US08187872B2
公开(公告)日：2012-05-29
申请号：US13277900
申请日：2011-10-20
CPC分类号： C12N15/86 , A61K39/0011 , A61K2039/5256 , C12N7/00 , C12N2740/15022 , C12N2740/15043 , C12N2770/36145 , Y02A50/466
摘要： Lentiviral vector particles comprising a Sindbis virus E2 glycoprotein variant and a lentiviral vector genome comprising a sequence of interest are provided. A lentiviral vector particle comprising: (a) an envelope comprising a Sindbis virus E2 glycoprotein variant; and (b) a lentiviral vector genome comprising a sequence of interest; wherein the E2 glycoprotein variant facilitates infection of dendritic cells by the lentiviral vector particle, and wherein the E2 glycoprotein variant has reduced binding to heparan sulfate compared to a reference sequence (HR strain).
摘要翻译： 提供包含辛德毕斯病毒E2糖蛋白变体和包含感兴趣序列的慢病毒载体基因组的慢病毒载体颗粒。 一种慢病毒载体颗粒，包括：（a）包含辛德毕斯病毒E2糖蛋白变体的包膜; 和（b）包含感兴趣序列的慢病毒载体基因组; 其中E2糖蛋白变体便于慢病毒载体颗粒感染树突状细胞，并且其中E2糖蛋白变体与参考序列（HR应变）相比具有减少的与硫酸乙酰肝素的结合。
-
3.发明授权Computer architecture and process of patient generation evolution, and simulation for computer based testing system 有权计算机体系结构与患者生成进化过程，以及基于计算机的测试系统的仿真公开(公告)号：US07725328B1
公开(公告)日：2010-05-25
申请号：US10704528
申请日：2003-11-07
IPC分类号： G06Q10/00
摘要： The present invention relates to a computer implemented system and method for generating and interacting with a multi-factoral patient simulation responsive to user queries and interventions.
摘要翻译： 本发明涉及一种计算机实现的系统和方法，用于响应于用户查询和干预而产生并与多因素患者模拟进行交互。
-
公开(公告)号：US07427499B2
公开(公告)日：2008-09-23
申请号：US10709674
申请日：2004-05-21
申请人： Kazuyoshi Sotoyama , Akinori Hiramatsu , Jin-zhong Xiao , Noritoshi Takahashi , Shizuki Kondo , Tomoko Yaeshima , Sachiko Takahashi
发明人： Kazuyoshi Sotoyama , Akinori Hiramatsu , Jin-zhong Xiao , Noritoshi Takahashi , Shizuki Kondo , Tomoko Yaeshima , Sachiko Takahashi
IPC分类号： C12N1/20
CPC分类号： A23C9/1234 , A23L29/065 , A23L33/135 , A23Y2220/13 , A23Y2300/55
摘要： 17It is intended to provide Bifidobacterium longum having the following bacteriological properties and microbial powders, foods and beverages containing this Bifidobacterium longum: (1) having such fermentation ability as to make a milk base medium to pH 4.6 or below; (2) showing a survival rate of 50% or more in the case of, after attaining pH 4.4 to 4.6 in a milk base medium, quenching and storing at 10° C. for two weeks; and (3) having such gastric juice tolerance as to yield a survival rate of 10% or more in the case of storing in artificial gastric juice (pH 3.0) at 37° C. for two hours.
摘要翻译： 本发明旨在提供具有以下细菌学特性的长双歧杆菌和含有这种长双歧杆菌的微生物粉末，食品和饮料：（1）具有如下发酵能力使得乳基培养基达到pH4.6或更低; （2）在乳基培养基中达到pH4.4〜4.6后，存活率为50％以上，在10℃下淬火储存2周; 和（3）具有这样的胃液耐受性，在将人造胃液（pH3.0）在37℃下储存2小时的情况下，生存率为10％以上。
-
公开(公告)号：US07723163B2
公开(公告)日：2010-05-25
申请号：US12126943
申请日：2008-05-26
申请人： Xue-song Xu , Zhi-gang Bai , Nan Xu , Jin-zhong Yao
发明人： Xue-song Xu , Zhi-gang Bai , Nan Xu , Jin-zhong Yao
IPC分类号： H01L21/00
CPC分类号： H01L23/49861 , H01L21/568 , H01L23/3107 , H01L23/49548 , H01L23/49558 , H01L24/48 , H01L24/97 , H01L2224/48091 , H01L2224/48247 , H01L2224/97 , H01L2924/00014 , H01L2924/01004 , H01L2924/01005 , H01L2924/01006 , H01L2924/01013 , H01L2924/01029 , H01L2924/01033 , H01L2924/01082 , H01L2924/14 , H01L2924/181 , H01L2224/85 , H01L2924/00012 , H01L2224/45099 , H01L2224/45015 , H01L2924/207
摘要： A method of forming a pre-molded lead frame having increased stand-offs includes the steps of attaching a first tape to a first side of the lead frame and a second tape to a second side of the lead frame. The taped lead frame is placed in a mold and a first flow of mold compound is initiated. The first flow of the mold compound fills a space between the first tape and an upper mold chase of the mold. A second flow of the mold compound then is initiated. The second flow of the mold compound fills the spaces between a die pad and leads of the lead frame. The first and second tapes then are removed from the lead frame. Improved stand-offs are provided because the first tape was depressed by the first flow of the mold compound.
摘要翻译： 形成具有增加的支架的预成型引线框的方法包括以下步骤：将第一带附着到引线框的第一侧，将第二带附接到引线框的第二侧。 带状引线框架放置在模具中，并开始第一模具化合物流。 模具化合物的第一流动填充第一带和模具的上模追逐之间的空间。 然后开始模具化合物的第二流程。 模具化合物的第二流动填充了管芯焊盘和引线框架的引线之间的空间。 然后将第一和第二带从引线框架移除。 提供了改进的支架，因为第一带被模具化合物的第一流动压下。
-
公开(公告)号：US20080111248A1
公开(公告)日：2008-05-15
申请号：US11718396
申请日：2005-10-31
申请人： Chee Seng Foong , Aminuddin Ismail , Wai Yew Lo , Bee Hoon Liau , Jin-Mei Liu , Jian-Hong Wang , Jin-Zhong Yao , Fu-Bin Song
发明人： Chee Seng Foong , Aminuddin Ismail , Wai Yew Lo , Bee Hoon Liau , Jin-Mei Liu , Jian-Hong Wang , Jin-Zhong Yao , Fu-Bin Song
CPC分类号： H01L25/0657 , H01L24/73 , H01L25/0652 , H01L2224/16225 , H01L2224/32145 , H01L2224/48091 , H01L2224/48145 , H01L2224/48227 , H01L2224/4824 , H01L2224/48465 , H01L2224/49109 , H01L2224/73265 , H01L2225/06506 , H01L2225/0651 , H01L2225/06517 , H01L2225/06572 , H01L2225/06586 , H01L2924/01079 , H01L2924/14 , H01L2924/15311 , H01L2924/1532 , H01L2924/16152 , H01L2924/00014 , H01L2924/00 , H01L2924/00012
摘要： A semiconductor package (100, 150, 200, 250), and method of forming the package, including a substrate (102, 102′, 202, 202′) having an opening (104, 104′, 204, 204′) formed therein. Contact pads (112, 112′, 212, 212′) are formed about a periphery of the opening on a first side of the substrate (106, 106′, 206, 206′) and a second opposing side (132, 132′, 232, 232′) of the substrate. A flip chip die (120, 120′, 220, 220′) is mounted to the substrate, having an active side (114, 114′, 214, 214′) mounted on a first side of the substrate and in electrical communication with at least some of the contact pads formed on the first side of the substrate. At least one wire bond die (110, 110′, 210, 210′) is mounted through the opening, with a non-active side mounted on the active side of the flip chip die. The wire bond die is in electrical communication with at least some of the plurality of contact pads formed on the second opposing side of the substrate.
摘要翻译： 一种形成封装的半导体封装（100,150,200,250）以及包括其中形成在其中的开口（104,104'，204,204'）的衬底（102,102'，202,202'）的方法， 。 在衬底（106,106'，206,206'）的第一侧上围绕开口的周边形成接触焊盘（112,112'，212,212'）和第二相对侧（132,132'， 232,232'）。 倒装芯片模具（120,120'，220,220'）安装到衬底上，具有安装在衬底的第一侧上并与之电气连通的有源侧（114,114'，214,214'） 在衬底的第一侧上形成的至少一些接触焊盘。 至少一个引线接合管芯（110,110'，210,210'）穿过开口安装，其中非有源侧安装在倒装芯片裸片的有源侧上。 引线接合管芯与形成在基板的第二相对侧上的多个接触焊盘中的至少一些电连接。
-
-
公开(公告)号：US08895725B2
公开(公告)日：2014-11-25
申请号：US13130130
申请日：2009-11-23
申请人： Shuguang Wang , Jin Zhong , Deyun Kong , Jue Hu , Bo Li , Wen Gao , Chunyan Gai , Changlong Zhuang , Haitao Mao
发明人： Shuguang Wang , Jin Zhong , Deyun Kong , Jue Hu , Bo Li , Wen Gao , Chunyan Gai , Changlong Zhuang , Haitao Mao
IPC分类号： A61K31/192 , C09B1/473 , A61K36/708 , A61K36/74 , A61K31/185 , A61K31/704 , A61K31/122 , A61K31/7004 , A61K36/482
CPC分类号： A61K31/122 , A61K31/185 , A61K31/192 , A61K31/7004 , A61K31/704 , A61K36/482 , A61K36/708 , A61K36/74
摘要： Use of 9,10-anthraquinone compounds of formula (I) or pharmaceutical salts thereof or plant extracts containing said compounds in the preparation of anti-HCV medicaments is disclosed, in which Y1 are Y2 are independently hydrogen, hydroxyl or groups of formula (II); and R1, R2, R3, R4, R5 and R6 are independently hydrogen, hydroxyl, carboxyl, cyano group, nitro group, groups of formula (III) or groups selected from those substituted or unsubstituted groups: amino, C1-C6 aliphatic hydrocarbon, C3-C7 cyclic aliphatic hydrocarbon, C1-C6 alkoxy, C2-C7 carbalkoxy, C1-C4 acyloxy, C6-C20 aryl, or 5 to 7 members heterocyclic or benzoheterocyclic thereof; or R5 and R6 form the group of formula (IV). The compounds of present invention are cheap, safe and effective because that they mostly come from traditional Chinese medicines and have better anti-HCV effects and lighter side effects.
摘要翻译： 公开了在制备抗HCV药物中使用式（I）的9,10-蒽醌化合物或其药用盐或含有所述化合物的植物提取物，其中Y 1为Y 2独立地为氢，羟基或式（II ）; 并且R 1，R 2，R 3，R 4，R 5和R 6独立地是氢，羟基，羧基，氰基，硝基，式（III）的基团或选自那些取代或未取代的基团的基团：氨基，C 1 -C 6脂族烃， C 3 -C 7环脂族烃，C 1 -C 6烷氧基，C 2 -C 7烷酰氧基，C 1 -C 4酰氧基，C 6 -C 20芳基或5至7元杂环或苯并杂环; 或R 5和R 6形成式（IV）的基团。 本发明化合物廉价，安全有效，因为它们主要来自中药，抗HCV效果更好，副作用更轻。
-
9.发明申请公开(公告)号：US20120039932A1
公开(公告)日：2012-02-16
申请号：US13277900
申请日：2011-10-20
IPC分类号： A61K39/00 , A61P37/04 , A61P35/00 , A61P31/16 , A61P31/20 , A61P31/22 , A61P31/14 , C12N15/867 , A61P31/18
CPC分类号： C12N15/86 , A61K39/0011 , A61K2039/5256 , C12N7/00 , C12N2740/15022 , C12N2740/15043 , C12N2770/36145 , Y02A50/466
摘要： Lentiviral vector particles comprising a Sindbis virus E2 glycoprotein variant and a lentiviral vector genome comprising a sequence of interest are provided. A lentiviral vector particle comprising: (a) an envelope comprising a Sindbis virus E2 glycoprotein variant; and (b) a lentiviral vector genome comprising a sequence of interest; wherein the E2 glycoprotein variant facilitates infection of dendritic cells by the lentiviral vector particle, and wherein the E2 glycoprotein variant has reduced binding to heparan sulfate compared to a reference sequence (HR strain).
摘要翻译： 提供包含辛德毕斯病毒E2糖蛋白变体和包含感兴趣序列的慢病毒载体基因组的慢病毒载体颗粒。 一种慢病毒载体颗粒，包括：（a）包含辛德毕斯病毒E2糖蛋白变体的包膜; 和（b）包含感兴趣序列的慢病毒载体基因组; 其中E2糖蛋白变体便于慢病毒载体颗粒感染树突状细胞，并且其中E2糖蛋白变体与参考序列（HR应变）相比具有减少的与硫酸乙酰肝素的结合。
-
公开(公告)号：US20110224414A1
公开(公告)日：2011-09-15
申请号：US13130130
申请日：2009-11-23
申请人： Shuguang Wang , Jin Zhong , Deyun Kong , Jue Hu , Bo Li , Wen Gao , Chunyan Gai , Changiong Zhuang , Haitao Mao
发明人： Shuguang Wang , Jin Zhong , Deyun Kong , Jue Hu , Bo Li , Wen Gao , Chunyan Gai , Changiong Zhuang , Haitao Mao
IPC分类号： C07H15/24 , C07C309/44 , C07C49/675
CPC分类号： A61K31/122 , A61K31/185 , A61K31/192 , A61K31/7004 , A61K31/704 , A61K36/482 , A61K36/708 , A61K36/74
摘要： Use of 9,10-anthraquinone compounds of formula (I) or pharmaceutical salts thereof or plant extracts containing said compounds in the preparation of anti-HCV medicaments is disclosed, in which Y1 are Y2 are independently hydrogen, hydroxyl or groups of formula (II); and R1, R2, R3, R4, R5 and R6 are independently hydrogen, hydroxyl, carboxyl, cyano group, nitro group, groups of formula (III) or groups selected from those substituted or unsubstituted groups: amino, C1-C6 aliphatic hydrocarbon, C3-C7 cyclic aliphatic hydrocarbon, C1-C6 alkoxy, C2-C7 carbalkoxy, C1-C4 acyloxy, C6-C20 aryl, or 5 to 7 members heterocyclic or benzoheterocyclic thereof; or R5 and R6 form the group of formula (IV). The compounds of present invention are cheap, safe and effective, because that they mostly conic from traditional Chinese medicines and have better anti-HCV effects and lighter side effects.
摘要翻译： 公开了在制备抗HCV药物中使用式（I）的9,10-蒽醌化合物或其药用盐或含有所述化合物的植物提取物，其中Y 1为Y 2独立地为氢，羟基或式（II ）; 并且R 1，R 2，R 3，R 4，R 5和R 6独立地是氢，羟基，羧基，氰基，硝基，式（III）的基团或选自那些取代或未取代的基团的基团：氨基，C 1 -C 6脂族烃， C 3 -C 7环脂族烃，C 1 -C 6烷氧基，C 2 -C 7烷酰氧基，C 1 -C 4酰氧基，C 6 -C 20芳基或5至7元杂环或苯并杂环; 或R 5和R 6形成式（IV）的基团。 本发明化合物廉价，安全有效，因为它们大多是中药复方，抗HCV效果更好，副作用更轻。
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.015 秒)
